Building Packaging Requirements for IATA Compliance for Regulatory Compliance

Introduction: Why IATA Compliance Matters in Clinical Trial Packaging

Clinical trial samples, especially those containing biological substances, must be packaged in accordance with the International Air Transport Association (IATA) Dangerous Goods Regulations (DGR). Non-compliance can lead to sample rejection, customs delays, or regulatory inspection findings.

Both the FDA and EMA expect sponsors and sites to adopt validated packaging procedures that align with IATA Packing Instructions (e.g., PI650 and PI602), particularly for infectious or diagnostic substances. This article outlines how to develop packaging requirements that are IATA-compliant, audit-proof, and aligned with global GCP expectations.

IATA Packaging Classifications for Clinical Samples

IATA categorizes clinical samples under:

• UN3373 – Biological Substance, Category B: Most diagnostic samples fall under this category and require Packing Instruction 650 (PI650)
• UN2814 or UN2900 – Category A Substances: Infectious substances that require Packing Instruction 602 (PI602)
• Exempt Human/Animal Specimens: Require basic leak-proof packaging but minimal labeling

Triple Packaging System: The Standard for PI650 Compliance

IATA mandates a triple packaging system for UN3373 shipments:

• Primary Receptacle: Leak-proof tube or vial with appropriate volume limits
• Secondary Packaging: Leak-proof, sealed container with sufficient absorbent material
• Outer Packaging: Rigid, durable box capable of protecting the contents during transit

Table: IATA PI650 Key Packaging Requirements

SOP Essentials for IATA-Compliant Packaging

Your SOP must cover:

• Classification of samples (Category A vs. B vs. Exempt)
• Selection criteria for validated packaging vendors
• Instruction on triple packaging assembly
• Labeling requirements, including IATA labels and hazard statements
• Documentation requirements (e.g., Shipper’s Declaration, manifest)
• Training and certification of site staff or couriers handling packaging

Case Study: FDA 483 Observation Due to Packaging Deficiency

During an FDA inspection of a U.S.-based oncology trial, a 483 was issued because samples were shipped in single-layer plastic containers without absorbent material. The outer packaging was not tested for integrity and failed during transport, resulting in a spill and customs seizure.

CAPA Measures Implemented:

• Revised SOP to mandate use of PI650-compliant triple packaging
• Site-level re-training and qualification on packaging assembly
• Implementation of packaging inspection checklist prior to courier handoff

Validation and Documentation of Packaging

Sponsors must ensure that all packaging systems used have been:

• Pre-qualified through validation testing including drop, leak, and pressure resistance
• Documented with Certificate of Conformance (CoC) from vendors
• Inspected at the site prior to dispatch
• Retained as part of the clinical trial master file (CTMF)

Training and Inspection Readiness

Staff involved in sample packaging must complete IATA Dangerous Goods training, valid for two years. Inspection readiness measures include:

• On-site visual verification of packaging materials and labeling
• Review of recent sample shipment records for adherence to SOPs
• Availability of vendor qualifications and training logs
• Corrective action documentation for any previous transport deviations

External Reference

For IATA’s official regulations and training modules, refer to IATA Dangerous Goods Regulations.

Conclusion

IATA-compliant packaging is a non-negotiable element of regulatory compliance in global clinical trials. From packaging material selection to staff training and SOP development, every aspect must be aligned with international standards and national regulations. Proactively building and validating your packaging system not only protects your samples but also ensures smooth inspections and uninterrupted trial progress.